Literature DB >> 15919002

Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?

Ted R Mikuls1, Kenneth G Saag.   

Abstract

Gout, a common form of inflammatory arthritis, has been markedly understudied relative to other rheumatologic conditions. As a result, evidence guiding clinical management in gout has traditionally been lacking. Burgeoning data suggests that quality of gout care in gout is frequently suboptimal. In this paper, we examine the evidence supporting gout management strategies in clinical practice. In addition, we examine consensus building efforts that have culminated in the recent publication of gout management quality indicators. We also discuss the need for future initiatives aimed at improving patient safety and quality of care in gout.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15919002     DOI: 10.1007/s11926-996-0046-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  80 in total

1.  Protracted uricosuric therapy in tophaceous gout.

Authors:  A B GUTMAN; T F YU
Journal:  Lancet       Date:  1957-12-21       Impact factor: 79.321

2.  The clinical and metabolic effects of benemid in patients with gout.

Authors:  J H TALBOTT; C BISHOP; B M NORCROSS; L M LOCKIE
Journal:  Trans Assoc Am Physicians       Date:  1951

3.  Piroxicam in treatment of acute gout high dose versus low dose.

Authors:  T Tumrasvin; U Deesomchok
Journal:  J Med Assoc Thai       Date:  1985-03

4.  Use of tenoxicam in patients with acute gouty arthritis.

Authors:  E F Valdés
Journal:  Eur J Rheumatol Inflamm       Date:  1987

5.  Withdrawal of longterm antihyperuricemic therapy in tophaceous gout.

Authors:  M F van Lieshout-Zuidema; F C Breedveld
Journal:  J Rheumatol       Date:  1993-08       Impact factor: 4.666

6.  Benzbromarone as a long-term uricosuric agent.

Authors:  R Bluestone; J Klinenberg; I K Lee
Journal:  Adv Exp Med Biol       Date:  1980       Impact factor: 2.622

7.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.

Authors:  Gregory C Borstad; Leslie R Bryant; Michael P Abel; Daren A Scroggie; Mark D Harris; Jeff A Alloway
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

8.  Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.

Authors:  Fernando Perez-Ruiz; Marcelo Calabozo; Jose I Pijoan; Ana M Herrero-Beites; Ana Ruibal
Journal:  Arthritis Rheum       Date:  2002-08

9.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

10.  Double-blind trial of feprazone and phenylbutazone in acute gout.

Authors:  J A Reardon; A Stockman; L G Darlington; J T Scott
Journal:  Curr Med Res Opin       Date:  1980       Impact factor: 2.580

View more
  2 in total

Review 1.  Uricase and other novel agents for the management of patients with treatment-failure gout.

Authors:  John S Sundy; Michael S Hershfield
Journal:  Curr Rheumatol Rep       Date:  2007-06       Impact factor: 4.686

2.  Trends in physician diagnosed gout and gout therapies in the US: results from the national ambulatory health care surveys 1993 to 2009.

Authors:  Eswar Krishnan; Linjun Chen
Journal:  Arthritis Res Ther       Date:  2013-11-06       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.